Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1993-10-22
1995-07-25
Saunders, David
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 723, 435 793, 435 794, 436512, 436518, 436813, G01N 33543, G01N 33574
Patent
active
054361320
ABSTRACT:
A method of determining tenascin in a cerebrospinal fluid sample by immunoassay, etc. is disclosed. The tenascin level in the cerebrospinal fluid serves as a glioma marker and thus the selective diagnosis of glioma is possible.
REFERENCES:
Lightner et al, 1989 Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy. J Cell Biol 108: 2483-2493.
Herlyn et al, 1991, Characterization of tenascin secreted by human melanoma cells. Cancer Res. 51: 4853-4858.
Bourdon et al, 1983. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43: 2796-2805.
Kimura et al, 1993. Determination of tenascin in human serum by the use of a new enzyme immunoassay. Biomed. Res. 14: 203-208.
Kimura Shigeki
Washizu Kinya
Yoshida Jun
Amano Pharmaceutical Co. Ltd.
Grun James L.
Saunders David
LandOfFree
Quantitative determination of tenascin as glioma marker does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quantitative determination of tenascin as glioma marker, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quantitative determination of tenascin as glioma marker will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-739017